116 related articles for article (PubMed ID: 3917530)
21. Heat inactivation of human immunodeficiency virus in lyophilized factor VIII and factor IX concentrates.
Piszkiewicz D; Bourret L; Lieu M; Hattley K; Thomas W; Cabradilla CD; Kingdon H; Menache D
Thromb Res; 1987 Jul; 47(2):235-41. PubMed ID: 3116716
[No Abstract] [Full Text] [Related]
22. Outbreaks of hepatitis A and emergence of new AIDS-associated agents: the need to add terminal 100 degrees C dry-heat sterilization to factor VIII and factor IX concentrates.
Guillaume TA
Vox Sang; 1993; 65(2):158. PubMed ID: 8212671
[No Abstract] [Full Text] [Related]
23. Hepatitis A transmission by factor IX concentrates: control by severe dry heat treatment at 80 degrees C.
Roberts P; Feldman P
Vox Sang; 1997; 73(3):189-90. PubMed ID: 9358623
[No Abstract] [Full Text] [Related]
24. Heat treatment at 100 degrees C of factor VIII and IX coagulation factor concentrates.
Teh LC; Woodfield DG
Med J Aust; 1993 Sep; 159(5):355-6. PubMed ID: 8361441
[No Abstract] [Full Text] [Related]
25. Factor VIII concentrate for hemophilia: comparison of two heat-treated products.
Walker IR; Pai MK; Blair BA; Johnston MA; Birkett NJ; Ofosu FA; Naylor DH
CMAJ; 1987 Jan; 136(2):150-2. PubMed ID: 3098401
[TBL] [Abstract][Full Text] [Related]
26. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
Ikematsu S; Yorifuji H; Arai M; Fukutake K
Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
[No Abstract] [Full Text] [Related]
27. Factor VIII and factor IX Sub-Committee. Recommendations for the assay of high-purity factor VIII concentrates.
Barrowcliffe TW
Thromb Haemost; 1993 Nov; 70(5):876-7. PubMed ID: 8128450
[No Abstract] [Full Text] [Related]
28. Properties of commercial factor IX concentrates.
Coan MH; Fournel MA; Mozen MM
Ann N Y Acad Sci; 1981; 370():731-46. PubMed ID: 6168231
[No Abstract] [Full Text] [Related]
29. Evaluation of two viral inactivation methods for the preparation of safer factor VIII and factor IX concentrates.
Heldebrant CM; Gomperts ED; Kasper CK; McDougal JS; Friedman AE; Hwang DS; Muchmore E; Jordan S; Miller R; Sergis-Davenport E
Transfusion; 1985; 25(6):510-5. PubMed ID: 3934800
[TBL] [Abstract][Full Text] [Related]
30. Virucidal treatment of clotting factor concentrates.
Mannucci PM; Colombo M
Lancet; 1988 Oct; 2(8614):782-5. PubMed ID: 2901620
[No Abstract] [Full Text] [Related]
31. Comparative efficacy of nonheated and heat-treated factor IX complex concentrate in treatment of hemophiliacs with inhibitors.
Schwartz RS; Ewing NP; Gorenc TJ; Spero JA
Am J Hematol; 1989 Jan; 30(1):22-6. PubMed ID: 2491929
[TBL] [Abstract][Full Text] [Related]
32. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis.
Morfini M; Lee M; Messori A
Thromb Haemost; 1991 Sep; 66(3):384-6. PubMed ID: 1746011
[No Abstract] [Full Text] [Related]
33. The survival of factor VIII (antihemophilic globulin) and factor IX (plasma thromboplastin component) in normal humans.
ADELSON E; RHEINGOLD JJ; PARKER O; STEINER M; KIRBY JC
J Clin Invest; 1963 Jul; 42(7):1040-7. PubMed ID: 14011051
[No Abstract] [Full Text] [Related]
34. In vitro characterization of various heat-treated prothrombin complex concentrates (PCC).
Yoshioka A; Nakagawa O; Uehara Y; Sakai T; Sugimoto M; Takamiya O; Tanaka I; Fukui H
Thromb Res; 1987 Aug; 47(4):449-58. PubMed ID: 2958958
[TBL] [Abstract][Full Text] [Related]
35. Hemophiliacs with HIV seroconversion associated with heat-treated products: are they actively infected?
Damjanovic V
JAMA; 1989 Mar; 261(9):1275. PubMed ID: 2492613
[No Abstract] [Full Text] [Related]
36. Factor VIII influences binding of factor IX and factor X to intact human platelets.
Muntean W; Leschnik B
Thromb Res; 1989 Sep; 55(5):537-48. PubMed ID: 2510357
[TBL] [Abstract][Full Text] [Related]
37. A standard nomenclature for factor VIII and factor IX gene mutations and associated amino acid alterations. On behalf of the ISTH SSC Subcommittee on Factor VIII and Factor IX.
Peake I; Tuddenham E
Thromb Haemost; 1994 Sep; 72(3):475-6. PubMed ID: 7855800
[No Abstract] [Full Text] [Related]
38. The role of platelets in intrinsic factor-Xa formation.
Walsh PN; Biggs R
Br J Haematol; 1972 Jun; 22(6):743-60. PubMed ID: 5037876
[No Abstract] [Full Text] [Related]
39. Factor VIII, factor IX and fibrinogen content in cryoprecipitate, fresh plasma and cryoprecipitate-removed plasma.
Bejrachandra S; Chandanayingyong D; Visudhiphan S; Tumliang S; Kaewkamol K; Siribunrit U
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():162-4. PubMed ID: 7886562
[TBL] [Abstract][Full Text] [Related]
40. Factor VIII coagulant antigen in clinical factor IX concentrates: characterisation of the molecular forms with the use of radiolabelled factor VIII: C antibodies.
Seghatchian MJ; Mackie IJ
Thromb Res; 1981 Dec 1-15; 24(5-6):473-8. PubMed ID: 6806933
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
